Marker Therapeutics Announces 2025 Corporate and Financial Results, Highlights Promising Lymphoma and Pancreatic Cancer Data

Marker Therapeutics reported year-end 2025 corporate and financial results, highlighting encouraging Phase 1 APOLLO data with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses. The company also strengthened manufacturing capabilities through a collaboration with Cellipont Bioservices and expanded its Board of Directors with Kathryn Penkus Corzo's appointment. A Phase 1 study update demonstrated a favorable safety profile across evaluated doses and durable responses.